Hidradenitis suppurativa management using tumor necrosis factor inhibitors in patients younger than 18 years: A series of 12 cases

J Am Acad Dermatol. 2020 Jul;83(1):199-201. doi: 10.1016/j.jaad.2020.02.071. Epub 2020 Mar 6.

Authors

Anne-Claire Fougerousse¹, Ziad Reguiai², Aude Roussel³, Pierre-André Bécherel⁴; Groupe d'Etudes Multicentriques (GEM) ResoVerneuil

Affiliations

¹ Dermatology Department, Hopital d'Instruction des Armées Bégin, Saint Mandé, France. Electronic address: ac.fougerousse@gmail.com.
² Dermatology Department, Polyclinique Courlancy, Reims, France.
³ Dermatology Department, Hopital d'Instruction des Armées Bégin, Saint Mandé, France.
⁴ Dermatology Department, Hopital Privé d'Antony, Antony, France.

PMID: 32151626
DOI: 10.1016/j.jaad.2020.02.071

No abstract available

Publication types

Letter

MeSH terms

Adalimumab / therapeutic use*
Adolescent
Female
Hidradenitis Suppurativa / drug therapy*
Humans
Infliximab / therapeutic use*
Male
Retrospective Studies
Tumor Necrosis Factor Inhibitors / therapeutic use*

Substances

Tumor Necrosis Factor Inhibitors
Infliximab
Adalimumab